ORPRO THERAPEUTICS INC

OrPro Therapeutics is a San Diego preclinical-stage biopharmaceutical company and Johnson & Johnson JLABS alumni addressing unmet medical needs in acute and chronic respiratory disease, ophthalmology, and oncology. Its lead asset ORP100S is based on the secreted human protein thioredoxin and has been shown to reduce inflammation, normalize mucociliary functions, and mitigate adverse effects of chemotherapy and radiation through a novel covalent-binding mechanism. The platform targets obstructive, oxidative, and inflammatory disorders with disease-modifying potential.